Royalty Report: Drugs, Cancer, Drug Discovery – Collection: 344542

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Cancer
  • Drug Discovery
  • Nanoparticles
  • Delivery
  • Vaccine
  • Biotechnology
  • Diagnostic
  • nucleic acid

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 344542

License Grant
The University grants an exclusive license, under the Licensed Patents, with the right to sublicense through multiple tiers, to make, have made, use, have used, offer for sale, have offered for sale, sell, have sold, import, have imported, export or have exported Licensed Products, and to practice any Licensed Method, within the Field in the Licensed Territory.
License Property
The University has produced inventions pertaining to drug delivery using targeted nanoparticles OCR 1670 and 3070.

The Patents are for Methods of Treatment with Drug Loaded Polymeric Materials.

Field of Use
The Field shall mean the use of Licensed Products containing a polymer and a therapeutic agent for the treatment of cancer. The Field shall specifically exclude the use of Licensed Products for the treatment of brain cancer; for therapeutic or prophylactic cancer vaccines, including where such vaccines incorporate an adjuvant but not an antigen; and for therapeutic or prophylactic vaccines for infectious diseases or allergies.

IPSCIO Record ID: 368651

License Grant
Licensor grants a worldwide, exclusive license to Licensor Patent Rights and Know-How to make, have made, use, import, offer to sell, and sell Product using Licensed Compound supplied by Licensor, or supplied by a third party, for use in the Field.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
Licensor, through its Drug Delivery Systems Division, has expertise and technology, with know-how and patents owned by Licensor, relating to toll-like receptor TLR 7 and/or 8 immune response modifier (IRM) compounds, formulations, conjugation, delivery, and manufacturing including proprietary IRM compounds such as resiquimod and others, that are useful as vaccine adjuvants.

The Compound is designated by Licensor as Resiquimod (R-848), S36212, 1-(4-aminobutoxy) -2-butyl-lH-imidazo (4,5-cl quinolin-4-amine and conjugates thereof.

Product shall mean any combination of a Licensee Antigen Presenting Cell or APC Targeting Technology vaccine with a Licensed Compound to be utilized as a Vaccine Adjuvant.

Vaccine Adjuvant shall mean a Licensed Compound which is used to induce, augment, fine-tune, enhance, or desensitize an antigen-specific immune response to an antigen contained in a vaccine or generated by a DNA vaccine for the therapeutic treatment of an existing disease or prophylactic use as protection against future disease, including desensitization to allergens. The antigen and the vaccine adjuvant may be admixed, delivered simultaneously, conjugated, or delivered separately, provided however, that the separate administration of the antigen and vaccine adjuvant is limited to the topical, dermal or mucosal or intradermal routes of administration and must be administered within 48 hours at substantially the same site and labeled as such by the applicable regulatory authority.

TLR compounds, also called TLR7 and TLR8 agonists, are small organically synthesized molecules that offer flexibility in formulating and route of delivery, and ease in manufacturing, unlike most other TLR agonists, which are much larger and not as easy to manufacture.

Field of Use
Licensor’s patented TLR immune response modifier compounds, which may be useful as vaccine adjuvants, will be used by Licensee to develop new vaccine products.  This license agreement provides a great opportunity to combine synergistic technologies designed to treat various cancers and infectious diseases.

The Field shall mean human prophylactic or therapeutic vaccination against any and all cancer disease states and selected infectious diseases.

This agreement focus is Cancer and the Infectious Diseases
– human immunodeficiency virus (HIV);
– human papillomavirus (HPV); and,
– hepatitis B virus (HBV).

IPSCIO Record ID: 345200

License Grant
In the original agreement, therapeutic and prophylactic vaccines were specifically excluded from the definition of Therapeutic Licensed Product under the License Agreement.

For clarification, the University has the right to grant exclusive licenses to third parties under the Patent Rights to develop, make, have made, use, sell, offer to sell, lease, and import any product that is solely a therapeutic or prophylactic vaccine and to develop and perform Licensed Processes solely to develop, make, have made, use, sell, offer to sell, lease and import any product that is solely a therapeutic or prophylactic vaccine.

License Grants, of the License Agreement shall be amended to read in its entirety as follows
The University grants to Company a license under the Patent Rights to develop, make, have made, use, sell, offer to sell, lease, and import Therapeutic Licensed Products and Diagnostic Licensed Products  in the Disease Field; develop, make, have made, use, sell, offer to sell, lease, and import Reagent Licensed Products; and develop and perform Licensed Processes except, solely, to develop, make, have made, use, sell, offer to sell, lease, and import any product that is solely a therapeutic or prophylactic vaccine, unless earlier terminated per the terms of this Agreement.

In order to establish an exclusive period for Company and University agrees that it shall not grant any other license under the Patent Rights (except University Sub 100Nm Biodegradable Polymer Spheres Capable Of Releasing Nucleic Acids) to develop, make, have made, use, sell, offer to sell, lease or import Therapeutic Licensed Products or Diagnostic Licensed Products in the Disease Fields in the Territory during the Term, or to develop or perform Licensed Processes, other than solely to develop, make, have made, use, sell, offer to sell, lease, or import any product that is solely a therapeutic or prophylactic vaccine, in the Disease Fields in the Territory during the Term, unless earlier terminated per the terms of this Agreement.

License Property
University is the owner or joint owner of certain Patent Rights relating to Formulation of Polymeric Particles for Prostate Cancer Targeting, and, Cancer Cell Targeting Using Nanoparticles.
Field of Use
The original agreement states Disease Field shall mean a field specific to a class of diseases. Examples include, but are not limited to cancer;  cardiovascular disease (atherosclerosis, congestive heart failure, etc.); immune/inflammatory disorders (rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, etc.); respiratory diseases (asthma, emphysema, central obstructive pulmonary disease, etc.); central nervous system disorders (Alzheimers disease, Parkinsons, etc.); and metabolic diseases (obesity, diabetes, etc.).

IPSCIO Record ID: 232446

License Grant
Licensor grants to the Japanese Licensee an option to have Licensor supply adjuvants owned or solely developed by Licensor to Licensee.

This agreement also includes a non-exclusive grant back from Licensee to Licensor.

License Property
This license relates to the L523S vaccine.  L523S is a RNA-binding protein as a potential therapeutic target for lung cancer.

Licensor Adjuvant Know-How shall mean any technical information, materials or know-how exclusively related to any adjuvant owned or controlled by Licensor, including without limitation the protein Leishmania Elongation Initiation Factor, known as LeIF, MPL, or any synthetic adjuvant.

Antigen(s) shall mean the antigens and/or protein and/or other physical form based on such antigens, such as peptides and/or nucleic acids(s) (DNA, RNA) delivered in any form, including recombinant vectors, to the extent such antigens are covered by one or more Valid Claim(s) of any of the Licensor Patents.

Field of Use
Licensees Licensed Field shall mean solid tumors in humans; provided, however, that the Licensed Field shall specifically exclude the use of any L523S Vaccine as an ex vivo adoptive immunotherapeutic and prophylactic for any and all cancers, including the use of dendritic cells as vaccines, any L523S Vaccine as a diagnostic and Antigens as targets for small molecules, therapeutics and/or prophylactics.

IPSCIO Record ID: 28794

License Grant
Licensor, a non-profit cancer treatment and research institution, granted the Company an exclusive, worldwide License under certain U.S. and foreign patents and patent applications owned or controlled by Licensor, or the Licensor's Patents, to develop, manufacture, use, market, sell, offer to sell, import and export certain products related to the development, manufacture, marketing and sale of therapeutic vaccines for the treatment of various cancers.

Subject to certain limitations, the Company will have the right to subLicense the foregoing rights granted.

Licensor grants an exclusive worldwide right and license under the Patent Rights, including the right to sublicense, to make, offer for sale, import, have made, use, lease and sell Licensed Products and to practice Licensed Processes in the Field of Use.

Licensor grants an exclusive, as it relates to commercial purposes, and not exclusive as it relates to non-commercial purposes, worldwide right and license under the Clinical Data, including the right to sublicense, to make, offer for sale, import, have made, use, lease and sell Licensed Products and to practice the Licensed Processes in the Field of Use.

Licensor grants a non-exclusive worldwide right and license under the Know How, including the right to sublicense, to make, offer for sale, import, have made, use, lease and sell Licensed Products and to practice the Licensed Processes in the Field of Use.

License Property
Licensor is the sole owner of certain Patent Rights and Know How relating to Polyvalent Conjugate Vaccines for Cancer.

The patents include, but are not limited to
Ganglioside-KLH Conjugate Vaccines Plus QS21;
Synthetic Compounds Which Bind To H. Pylori And Uses Thereof;
Alpha-O-Linked Glycycoconjugates with Clustered (2,6)-ST Epitopes, Methods of Preparation and Uses Thereof; and,
Polyvalent Conjugate Vaccine for Cancer.

Field of Use
The Field of Use shall mean monovalent and multi-molecular polyvalent cancer vaccines, except that, for the Globo H antigen, Field of Use shall mean multi-molecular polyvalent cancer vaccines. Multi-molecular polyvalent cancer vaccine means a cancer vaccine containing more that one type of antigen but not in the same molecule.

IPSCIO Record ID: 110461

License Grant
The University grants to Licensee and its Affiliates the exclusive license in the Territory with the right to grant sublicenses to others, under the Patent Rights, to make, have made, use, sell, import and offer for sale Products and to practice Processes.

Licensor grants to the Licensee the authority to make application for Patents, in the name of the Licensor.

License Property
The licensed patent applications relate to a Modified Heat Shock Protein-Antigenic Peptide Complex.
Field of Use
The licensed patent is in the area of the use of heat shock proteins for the development of therapeutic and prophylactic vaccines for cancer and infectious diseases (the 'Field').

IPSCIO Record ID: 344540

License Grant
University grants a license under the patent rights to
—  develop, make, have made, use, sell, offer to sell, lease, and import Therapeutic Licensed Products and Diagnostic Licensed Products in the Disease Fields;
—  develop, make, have made, use, sell, offer to sell, lease, and import Reagent Licensed Products; and,
—  develop and perform Licensed Processes, unless earlier terminated per the terms of this Agreement.

For the Limited-Term Option to License Improvements Dominated by Patent –
— Subject to any obligations of University to third parties, University grants an exclusive option to add to the Patent Rights of this Agreement Universitys patent rights in inventions conceived and reduced to practice, before June 1, 2010;
— dominated by the Patent Rights licensed under this Agreement on the Effective Date and,
— arising from research performed solely in the laboratory, and,
— directly related to a Fully funded project as of, or within four (4) months of, Companys being provided a copy of the related invention disclosure form by University.

This agreement is exclusive for Therapeutic and Diagnostic products, but may be exclusive or non-exclusive for the Reagent products.

License Property
University is the owner or joint owner of certain Patent Rights relating to
Non-Linear Hydrophilic-Hydrophobic Biopolymers,
Biodegradable Microparticles and Injectable Nanospheres,
Sub 100Nm Biodegradable Polymer Spheres Capable of Releasing Nucleic Acids,
Targeted Delivery of Nano- or Microparticles Using Nucleic Acid Ligands,
Bioadhesive Polymers-Coated Controlled Release Polymer Particles as Efficient Oral Delivery Vehicles for Biopharmaceuticals,
High Throughput Synthesis of Functionalized Materials,
Method ofldentifying Particles with Desired Characteristics from a Library of Particles,
Formulation of Polymeric Particles for Prostate Cancer Targeting,
Multi-Block Co-Polymer for the Development of Functional Particles,
Nanocrystal-Aptamer-Doxorubicin Multifunctional Conjugate System for Cancer Diagnosis and Treatment,
Method of isolating Nucleic Acid Ligands that are Taken up by Cells and Uses Thereof,
Affibodies as a Targeting Ligand in Controlled Drug Delivery Systems,
Receptor Triggered Controlled Drug Delivery Systems to Cross,
Endothelial and/or Epithelial Cell Layers and their Method of Preparation,
Reverse Micelle Nanoprecipitation A Method for Encapsulating Nucleic Acids in Biodegradable Polymers, and, Amphiphilic Compound Assisted Polymeric Particles for Targeted Delivery.

Licensed Products shall mean Reagent, Therapeutic and Diagnostic Licensed Products.

Reagent Licensed Product shall mean any product used primarily as a reagent for research or other non-therapeutic and non-diagnostic purpose that, in whole or in part
– absent the license granted hereunder, would infringe one or more claims of the Patent Rights; or
– is manufactured by using a Licensed Process or that, when used, practices a Licensed Process.

Therapeutic Licensed Product shall mean any therapeutic product except therapeutic or prophylactic vaccines (which are specifically excluded from the definition of Therapeutic Licensed Product), used for a therapeutic purpose that, in whole or in part
– absent the license granted hereunder, would infringe one or more claims of the Patent Rights; or
– is manufactured by using a Licensed Process or that, when used, practices a Licensed Process.

Diagnostic Licensed Product shall mean any product used for a diagnostic purpose that, in whole or in part
– absent the license granted hereunder, would infringe one or more claims of the Patent Rights; or
– is manufactured by using a Licensed Process or that, when used, practices a Licensed Process.

Field of Use
Disease Field shall mean a field specific to a class of diseases. Examples include, but are not limited to cancer;  cardiovascular disease (atherosclerosis, congestive heart failure, etc.); immune/inflammatory disorders (rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, etc.); respiratory diseases (asthma, emphysema, central obstructive pulmonary disease, etc.); central nervous system disorders (Alzheimers disease, Parkinsons, etc.); and metabolic diseases (obesity, diabetes, etc.).

IPSCIO Record ID: 362510

License Grant
The University grants an exclusive, worldwide, sublicensable license under the Patent Rights to make, have made, use, market, sell, offer to sell, lease and import Licensed Products in the Field.
License Property
University is the owner of the Patent Rights relating to
Other Transaction Authority for Prototype Agreement (OTA) 92-14, 98-24, 98-25, 98-36, 02-001, 02-028, 02-080, 03-025, 03-065, 07-019, and 07-055.
Field of Use
The Fields of use shall mean any and all applications in humans.

Licensee and its Parent are focused on the development of next-generation vaccines to prevent or treat cancers and chronic infectious diseases.

IPSCIO Record ID: 344541

License Grant
University grants an exclusive license, with the right to sublicense, to make, have made, use, have used, import, have imported, offer for sale, have offered for sale, have sold and sell the licensed products in the United States and worldwide under the Patent rights in the Licensed Field.
License Property
The license relates to an invention(s) entitled PSMA Targeted Nanoparticles for Therapy of Prostate Cancer. PSMA is a clinically-validated tumor marker expressed on prostate cancer cells and the blood vessels of many types of non-prostate solid tumors.
Field of Use
The Licensed field shall mean all fields.  Licensee is a clinical-stage nanomedicine platform company developing novel targeted and programmable therapeutics.

IPSCIO Record ID: 286054

License Grant
University grants Licensee an exclusive (even as to University), worldwide, irrevocable, non-transferable  license in the Biodiagnostics Field, with the right to sublicense, under the University Patent Rights, to make, have made, use, sell, offer for sale, export and import Licensed Products within the Biodiagnostics Field.

University grants Licensee an exclusive (even as to University), worldwide, irrevocable, non-transferable  license in the Biodiagnostics Field, with the right to sublicense, under the Joint Patent Rights, to make, have made, use, sell, offer for sale, export and import Licensed Products within the Biodiagnostics Field.

University grants Licensee a nonexclusive, worldwide, irrevocable, non-transferable license in the Biodiagnostics Field, with the right to sublicense, to use the Technical Information to design, develop, manufacture, have manufactured, sell, offer for sale, import, and export the Licensed Products within the Biodiagnostics Field.

Each party acknowledges that the other party is a co-owner of an equal and undivided interest in and to the Joint Patent Rights.

License Property
University Patent Rights means
6,709,825 – Nanoparticles having oligonucleotides attached thereto and uses therefor
6,902,895 – Nanoparticles having oligonucleotides attached thereto and uses therefor
7,115,688 – Nanoparticles with polymer shells

Joint Patent Rights means
6361944 – Nanoparticles Having Oligonucleotides Attached Thereto And Uses Therefore

Biobarcode Technology means analysis where oligonucleotides act as surrogate targets or reporter molecules.

Nanoparticle Technology means any technology in the Biodiagnostics Field involving a particle where no single dimension is greater than 100 nm.

Field of Use
Biodiagnostics Field means the qualitative or quantitative in vitro analysis, testing, measurement, or detection of the following specific field subset and target combinations (including products that incorporate in vivo harvesting of test samples for ex vivo testing)
Biodiagnostics Field Subsets – Targets

Human and animal testing (Includes pharmaceutical and biotechnology discovery and development) –
Nucleic acids, proteins, peptides, amino acids, metabolites, therapeutic drugs, drugs of abuse, hormones, sugars, lipids and lipoproteins
Plants – Nucleic acids, proteins, peptides, phytotoxins
Environmental – Pathogens, toxins and biological contaminants

The Biodiagnostics Field excludes the following subject matter and all Biodiagnostics Field applications thereof
(a) therapeutics (including in vitro and in vivo therapy and controlling, modulating, or otherwise affecting gene expression);
(b) technology relating to or derived from dip-pen nanolithography;
(c) environmental applications other than as set forth above;
(d) prismatic particles (including methods of manufacture and uses thereof); and
(e) coordination polymers (including methods of manufacture and uses thereof).
For purposes of clarity, other than with respect to Biobarcode Technology or an Invention where the Licensed Product itself is the surrogate for the target listed above, the term “detection” means the detection of the actual target listed above and not the detection of a surrogate, not listed above, for the target.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.